Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022

Abstract Background From August to October 2022, a therapeutic efficacy study of Niger’s first-line antimalarial, artemether-lumefantrine (AL), was conducted in four sites (Aderbissinat, Boboye, Aguié, and Baban Tabki) to evaluate its therapeutic efficacy and investigate for molecular markers of ant...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ibrahim Maman Laminou, Sanoussi Maman Kabirou, Ibrahima Issa Arzika, Abdou Yahaya, Jehan Ahmed, Awa Bineta Deme, Mamadou Alpha Diallo, Bassirou Ngom, Amy Gaye, Aïta Sene, Djiby Sow, Eric Coulibaly, Zilahatou Bahari-Tohon, Elisha Sanoussi, Daniel Koko, Irene Cavros
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-12-01
Saila:	Malaria Journal
Gaiak:	Efficacy Artemether-lumefantrine Niger Antimalarial resistance Molecular surveillance
Sarrera elektronikoa:	https://doi.org/10.1186/s12936-025-05679-x
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!